Amgen’s T-cell engager notches major new lung cancer victory

Data ReadoutpositiveImdelltraPositive

AI Analysis

Summary

Amgen announced positive clinical data for its T-cell engager Imdelltra in combination with a checkpoint inhibitor, demonstrating improved overall survival in patients with advanced lung cancer.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

T cell engager Imdelltra combined with checkpoint inhibitor demonstrated improved overall survival in patients with advanced lung cancer

Importance:7/10

Sentiment:

0.85

oncologyimmunotherapyT-cell engagercheckpoint inhibitorlung cancerclinical trial

Related Companies

$AMGN

Read the original article

Published by Endpoints News on September 8, 2026 5:53 PM

Read Original